Sirtex Medical's DOORwaY90 Study Demonstrates 100% Local Tumor Control with SIR-Spheres®, Setting a New Benchmark in Y-90 for HCC PR Newswire WOBURN, Mass., April 13, 2026 The DOORwaY90 study met its ...
Sirtex announces SIR-Spheres ® portfolio expansion to include the FLEXdose SELECT 3mL vial configuration allowing for more patient-specific Y-90 selective treatment plans ...
WOBURN, Mass., July 7, 2025 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of interventional oncology solutions, today announced that the U.S. Food and Drug Administration (FDA) ...
First prospective multicenter U.S.-based trial for indication expansion of SIR-Spheres ® Y-90 resin microspheres taking place in 15 sites across the U.S. WOBURN, Mass., May 10, 2021 /CNW/ -- Sirtex ...
Ranbaxy Laboratories Ltd has signed an exclusive in-licensing agreement with Sirtex Medical Pvt Ltd (Sirtex), Australia, to promote and market Sirtex''s liver cancer product, SIR-Spheres, which has ...
WOBURN, Mass., April 13, 2026 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of interventional oncology and embolization solutions, today announced landmark 12-month results from ...
Expanded indication makes SIR-Spheres ® the first and only radioembolization therapy in the U.S. approved to treat both unresectable hepatocellular carcinoma and metastatic colorectal cancer WOBURN, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results